SG11201408770RA - Compounds and therapeutic uses thereof - Google Patents
Compounds and therapeutic uses thereofInfo
- Publication number
- SG11201408770RA SG11201408770RA SG11201408770RA SG11201408770RA SG11201408770RA SG 11201408770R A SG11201408770R A SG 11201408770RA SG 11201408770R A SG11201408770R A SG 11201408770RA SG 11201408770R A SG11201408770R A SG 11201408770RA SG 11201408770R A SG11201408770R A SG 11201408770RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cmpd
- bid
- utah
- parent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/58—Amidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 3 January 2014 (03.01.2014) WIPOIPCT (10) International Publication Number WO 2014/004884 A1 (51) International Patent Classification: C07D 213/69 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/048274 27 June 2013 (27.06.2013) English English (30) Priority Data: 61/665,297 27 June 2012 (27.06.2012) (71) Applicant: ALZHEIMER'S INSTITUTE OF AMER ICA, INC. [US/US]; 7837 Parallel Parkway, Kansas City. Kansas 66112-2493 (US). (72) Inventors: WILLARDSEN, J. Adam; 14413 Bridgefield Dr., Draper, Utah 84020 (US). LOCKMAN, Jeffrey W.; 26 Dunbar Drive, Princeton Junction, New Jersey 08550 (US). MURPHY, Brett R.; 60770 Salt Creek Rd„ Coil- bran, Colorado 81624 (US). JUDD, Weston R.; 1284 South Cave Hollow Lane, Farmington, Utah 84025 (US). YAGER, Kraig M.; 633 Lincoln Place, Murray, Utah 84107 (US). (74) Agent: ECHOLS, Kelly A.; STOEL RIVES LLP, 201 So. Main Street, Suite 1100, One Utah Center, Salt Lake City, Utah 84111 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Ug (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (54) Title: COMPOUNDS AND THERAPEUTIC USES THEREOF o > •o (D £ •t 00 00 •t o o Vehicle Parent Cmpd. A (3mpk, BID) Parent Cmpd. A (4mpk, BID) Parent Cmpd. A (5mpk, BID) Parent Cmpd. A (7mpk, BID) Parent Cmpd. A (9mpk, BID) 10 15 time (days) Figure O CJ o & (57) Abstract: The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complica tions associated with these diseases and disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261665297P | 2012-06-27 | 2012-06-27 | |
PCT/US2013/048274 WO2014004884A1 (en) | 2012-06-27 | 2013-06-27 | Compounds and therapeutic uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408770RA true SG11201408770RA (en) | 2015-01-29 |
Family
ID=49783870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408770RA SG11201408770RA (en) | 2012-06-27 | 2013-06-27 | Compounds and therapeutic uses thereof |
Country Status (16)
Country | Link |
---|---|
US (1) | US20150344426A1 (en) |
EP (1) | EP2867209A4 (en) |
JP (1) | JP2015522028A (en) |
KR (1) | KR20150024932A (en) |
CN (1) | CN104768931A (en) |
AU (1) | AU2013284487A1 (en) |
BR (1) | BR112014032917A2 (en) |
CL (1) | CL2014003560A1 (en) |
IL (1) | IL236499A0 (en) |
IN (1) | IN2015KN00240A (en) |
MA (1) | MA37808A1 (en) |
MX (1) | MX2015000101A (en) |
PH (1) | PH12015500179A1 (en) |
RU (1) | RU2015102278A (en) |
SG (1) | SG11201408770RA (en) |
WO (1) | WO2014004884A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3131881A4 (en) | 2014-04-18 | 2017-09-06 | Millennium Pharmaceuticals, Inc. | Quinoxaline compounds and uses thereof |
WO2015176135A1 (en) * | 2014-05-22 | 2015-11-26 | The University Of Sydney | Omega-3 analogues |
EP3247705B1 (en) | 2015-01-20 | 2019-11-20 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof as nampt inhibitors |
ES2879434T3 (en) | 2015-07-23 | 2021-11-22 | Inst Curie | Use of a combination of Dbait molecule and PARP inhibitors for cancer treatment |
FR3047552A1 (en) * | 2016-02-05 | 2017-08-11 | Air Liquide | OPTIMIZED INTRODUCTION OF A DIPHASIC MIXED REFRIGERANT CURRENT IN A NATURAL GAS LIQUEFACTION PROCESS |
WO2017170826A1 (en) * | 2016-03-30 | 2017-10-05 | 味の素株式会社 | Compound having enhancing activity for glucagon-like peptide-1 receptor actions |
KR101869794B1 (en) * | 2016-07-20 | 2018-06-21 | 연세대학교 산학협력단 | Phamaceutical composition for preventing or treating refractory, relapsed, or metastatic cancer |
US10683387B2 (en) | 2016-10-04 | 2020-06-16 | Massachusetts Institute Of Technology | Bottlebrush copolymers and uses thereof |
WO2019006425A1 (en) | 2017-06-30 | 2019-01-03 | Massachusetts Institute Of Technology | Brush-arm star polymer imaging agents and uses thereof |
US10716858B2 (en) | 2017-06-30 | 2020-07-21 | Massachusetts Institute Of Technology | Branched multi-functional macromonomers and uses thereof |
KR101937126B1 (en) * | 2018-06-15 | 2019-01-10 | 연세대학교 산학협력단 | Phamaceutical composition for preventing or treating refractory, relapsed, or metastatic cancer |
EP3837266A1 (en) | 2018-08-17 | 2021-06-23 | Massachusetts Institute of Technology | Degradable polymers of a cyclic silyl ether and uses thereof |
US20210369681A1 (en) * | 2018-10-22 | 2021-12-02 | Yale University | Identification of PPM1D mutations as a novel biomarker for NAMPTi sensitivity |
US20210113701A1 (en) * | 2019-10-16 | 2021-04-22 | Massachusetts Institute Of Technology | Brush prodrugs and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1494702A (en) * | 2000-11-21 | 2002-06-03 | Leo Pharma As | Cyanoguanidine prodrugs |
KR101010871B1 (en) * | 2002-05-17 | 2011-01-26 | 레오 파마 에이/에스 | Cyanoguanidine prodrugs |
US7253193B2 (en) * | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
US8871747B2 (en) * | 2008-08-29 | 2014-10-28 | Topotarget A/S | Urea and thiourea derivatives |
CN102869261A (en) * | 2010-03-01 | 2013-01-09 | 瑞科西有限公司 | Compounds and therapeutic uses thereof |
AU2011295724B2 (en) * | 2010-09-03 | 2016-05-12 | Forma Tm, Llc | 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl] amino} benzene - sulfone derivatives as NAMPT inhibitors for therapy of diseases such as cancer |
-
2013
- 2013-06-27 JP JP2015520521A patent/JP2015522028A/en active Pending
- 2013-06-27 AU AU2013284487A patent/AU2013284487A1/en not_active Abandoned
- 2013-06-27 EP EP13810056.5A patent/EP2867209A4/en not_active Withdrawn
- 2013-06-27 SG SG11201408770RA patent/SG11201408770RA/en unknown
- 2013-06-27 MA MA37808A patent/MA37808A1/en unknown
- 2013-06-27 CN CN201380045302.4A patent/CN104768931A/en active Pending
- 2013-06-27 IN IN240KON2015 patent/IN2015KN00240A/en unknown
- 2013-06-27 WO PCT/US2013/048274 patent/WO2014004884A1/en active Application Filing
- 2013-06-27 RU RU2015102278A patent/RU2015102278A/en not_active Application Discontinuation
- 2013-06-27 BR BR112014032917A patent/BR112014032917A2/en not_active IP Right Cessation
- 2013-06-27 KR KR20157002268A patent/KR20150024932A/en not_active Application Discontinuation
- 2013-06-27 MX MX2015000101A patent/MX2015000101A/en unknown
-
2014
- 2014-12-24 US US14/582,641 patent/US20150344426A1/en not_active Abandoned
- 2014-12-28 IL IL236499A patent/IL236499A0/en unknown
- 2014-12-29 CL CL2014003560A patent/CL2014003560A1/en unknown
-
2015
- 2015-01-27 PH PH12015500179A patent/PH12015500179A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PH12015500179A1 (en) | 2015-04-06 |
MA37808A1 (en) | 2018-03-30 |
CN104768931A (en) | 2015-07-08 |
IN2015KN00240A (en) | 2015-06-12 |
WO2014004884A1 (en) | 2014-01-03 |
EP2867209A1 (en) | 2015-05-06 |
EP2867209A4 (en) | 2015-11-25 |
AU2013284487A1 (en) | 2015-02-19 |
IL236499A0 (en) | 2015-02-26 |
BR112014032917A2 (en) | 2017-06-27 |
US20150344426A1 (en) | 2015-12-03 |
KR20150024932A (en) | 2015-03-09 |
CL2014003560A1 (en) | 2015-11-27 |
JP2015522028A (en) | 2015-08-03 |
RU2015102278A (en) | 2016-08-20 |
MX2015000101A (en) | 2015-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408770RA (en) | Compounds and therapeutic uses thereof | |
SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
SG11201910027YA (en) | Bispecific antibody against ox40 and ctla-4 | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201408614SA (en) | Flexible assembly machine, system and method | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201408261UA (en) | Syringe | |
SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
SG11201407372UA (en) | Nampt inhibitors | |
SG11201408094YA (en) | Neprilysin inhibitors | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201900501RA (en) | Cannabis composition | |
SG11201407349UA (en) | Proliposomal testosterone formulations | |
SG11201407898WA (en) | Electrode testing apparatus | |
SG11201407340YA (en) | Treatment of myelosuppression | |
SG11201407200TA (en) | Liquid formulation | |
SG11201906744VA (en) | Core/shell structure platform for immunotherapy | |
SG11201808215SA (en) | Aluminum alloys having iron, silicon, vanadium and copper, and with a high volume of ceramic phase therein |